Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113097372 | 11309737 | 2 | F | 20141019 | 20160910 | 20150724 | 20160917 | EXP | US-UCBSA-2014015849 | UCB | 51.24 | YR | F | Y | 0.00000 | 20160917 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113097372 | 11309737 | 1 | PS | LEVETIRACETAM. | LEVETIRACETAM | 1 | 500 MG/6 DAILY | 116283 | 0 | ||||||||||
| 113097372 | 11309737 | 2 | SS | LEVETIRACETAM. | LEVETIRACETAM | 1 | 500 MG/7A DAY | 120119 | 0 | ||||||||||
| 113097372 | 11309737 | 3 | SS | LEVETIRACETAM. | LEVETIRACETAM | 1 | 4000 MG | 120119 | 0 | ||||||||||
| 113097372 | 11309737 | 4 | C | LEVETIRACETAM. | LEVETIRACETAM | 1 | UNK | N | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 113097372 | 11309737 | 1 | Seizure |
| 113097372 | 11309737 | 4 | Seizure |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 113097372 | 11309737 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 113097372 | 11309737 | Off label use | |
| 113097372 | 11309737 | Overdose | |
| 113097372 | 11309737 | Seizure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 113097372 | 11309737 | 1 | 201203 | 0 |